Facebook
X
LinkedIn
Forward
Barrier to Breakthrough: Mastering Targeted Topicals for Skin Barrier Repair in Pediatric AD
Atopic dermatitis (AD) is a chronic inflammatory condition that is exacerbated by disruption of the skin barrier, yet management remains challenging due to the limitations of traditional agents and the need for optimal safety and tolerability in pediatric populations. The recently expanded indications for PDE4 inhibitors, JAK inhibitors, and AhR agonists, represent a major therapeutic shift by offering non-steroidal treatment options. Health care professionals who treat pediatric patients with AD must be familiar with the latest clinical efficacy and safety data to effectively leverage these new treatments. This on-demand session, recorded during the 2026 Masters of Pediatric Dermatology, will educate participants on AD pathophysiology and the latest clinical data for targeted topicals in pediatric patients, providing expert-guided strategies to optimize management.
Target Audience
The activity is designed for an audience of US-based dermatologists, pediatricians, pediatric dermatologists, nurses and allied health providers (nurse practitioners and physician assistants).
Learning Objectives
Upon completion of the educational activity, participants should be better able to:
- Describe the role of skin barrier dysfunction in atopic dermatitis pathogenesis to rationalize selection of appropriate topical therapy for pediatric patients.
- Critically analyze clinical data for new targeted topical therapies to inform treatment selection in pediatric atopic dermatitis.
- AD pathophysiology
- Epithelial barrier hypothesis
- Guidelines for acute and chronic management
- Topical and systemic treatment landscape
- Pearls for topical treatment selection and application
- Clinical efficacy, safety, and tolerability data
- JAK inhibitors
- PDE4 inhibitors
- AhR agonists
- Emerging treatment pipeline
 | |
Peter A. Lio, MD |
Credit provided by AKH Inc., Advancing Knowledge in Healthcare
In support of improving patient care, this activity has been planned and implemented by AKH Inc., Advancing Knowledge in Healthcare and Tarsus Cardio dba LiVDerm. AKH Inc., Advancing Knowledge in Healthcare is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
This activity was planned by and for the healthcare team, and learners will receive 0.25 Interprofessional Continuing Education (IPCE) credit for learning and change.
Physician
AKH Inc., Advancing Knowledge in Healthcare designates this enduring activity for a maximum of 0.25 AMA PRA Category 1 Credit(s)TM. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nurses
0.25 ANCC contact hours.
Physician Assistant
AKH Inc., Advancing Knowledge in Healthcare has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.25 AAPA Category 1 CME credits. PAs should only claim credit commensurate with the extent of their participation.
Commercial Support
This activity is supported by an educational grant from Arcutis Biotherapeutics, Inc.
Disclosure
It is the policy of AKH Inc. to ensure independence, balance, objectivity, scientific rigor, and integrity in all of its continuing education activities. The author must disclose to the participants any significant relationships with ineligible companies whose products or devices may be mentioned in the activity or with the commercial supporter of this continuing education activity. Identified conflicts of interest are mitigated by AKH prior to accreditation of the activity. AKH planners and reviewers have no relevant financial relationships to disclose.
DISCLOSURES | ||
Name | Relationship | Commercial Interest |
Peter Lio, MD | Advisor | Alphyn Biologics, AbbVie, Almirall, Amyris, Apogee, Arcutis, ASLAN, Astria Therapeutics, Boston Skin Science, Bristol-Myers Squibb, Burts Bees, Castle Biosciences, Codex Labs, Concerto Biosci, ClearRx, Dermavant, Eli Lilly, Galderma, Kenvue, LEO Pharma, Lipidor, L'Oreal, Merck, Midwest Bioprocessing, Micreos, MyOR Diagnostics, Nektar Therapeutics, Nia Health, Pelthos Therapeutics, Phyla, Regeneron/Sanofi Genzyme, Sibel Health, Skinfix, Soteri Skin, Stratum Biosciences, Sun Pharma, Theraplex, Thimble Health, Topaz Biosciences,Inc., UCB, Unilever, Verdant Scientific, Verrica, Yobee Care |
Individual stocks and stock options | Alphyn Labs, Codex Labs, Concerto Biosci, Midwest Bioprocessing, Soteri Skin, Stratum Biosciences, Topaz Biosciences, Inc., Yobee Care, Verdant Scientific | |
Royalties or patent beneficiary | Theraplex AIM - Theraplex | |
Speaker | AbbVie, Arcutis, Eli Lilly, Galderma, Hyphens Pharma, Incyte, La Roche-Posay/L'Oreal, MyOR Diagnostics, Pfizer, Pierre-Fabre Dermatologie, Regeneron/Sanofi Genzyme, Verrica | |
Dorothy Caputo, MA, BSN, RN, President | N/A | Nothing to disclose |
Rebecca Lakofsky, BSN, RN | N/A | Nothing to disclose |
Michele Bielarski, RN (planner/reviewer) | N/A | Nothing to disclose |
AKH Inc Staff and Planners | N/A | Nothing to disclose |
Tarsus dba LiVDerm Staff and Planners | N/A | Nothing to disclose |
All of the relevant financial relationships listed for these individuals have been mitigated. | ||
Disclosure of Unlabeled Use and Investigational Product
This educational activity may include discussion of uses of agents that are investigational and/or unapproved by the FDA. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
This course is designed solely to provide the healthcare professional with information to assist in his/her practice and professional development and is not to be considered a diagnostic tool to replace professional advice or treatment. The course serves as a general guide to the healthcare professional, and therefore, cannot be considered as giving legal, nursing, medical, or other professional advice in specific cases. AKH Inc. specifically disclaims responsibility for any adverse consequences resulting directly or indirectly from information in the course, for undetected error, or through participant's misunderstanding of the content.
If you would like to opt out from future communications from AKH please send an email to [email protected] with your information with "Opt Out" in the subject line.
AKH Privacy Policy (link: https://akhcme.com/akhcme/pages/privacy)
Available Credit
- 0.25 AAPA Category I CME
- 0.25 AMA PRA Category 1 Credit™
- 0.25 ANCC
- 0.25 Participation
Required Hardware/software
A computer with an internet connection
Other additional software may be required such as PowerPoint or Adobe Acrobat Reader.
PC Microsoft Internet Explorer 11 or later, Windows Edge browser, Mozilla Firefox, and Google Chrome For HTML Client – Google Chrome (v70.0 & above), Mozilla Firefox (v65.0 & above), and Edge (v42.0 & above)
| MAC Mozilla Firefox, Apple Safari, Google Chrome For HTML Client – Google Chrome (v70.0 & above), Apple Safari (v12.0 & above), and Mozilla Firefox (v65.0 & above)
|
Criteria for Success
In order to receive CME/CE credits, participants must complete the pre-assessment questions, post-assessment, and program evaluation. Participants must also score at least 70% on the post-assessment. Certificates will be distributed online at the conclusion of the activity. Your online certificate will be saved within your Dashboard or Transcript, which you can access at any time.